12 recruiting, 9 active not recruiting, 8 completed, 3 terminated. 21 Phase 2, 9 Phase 1, 6 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow entrectinib: new trials by email Literature Review of entrectinib trials Research Report on entrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 52 | 2026-05-01 | 2026-11-03 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| Study on the Mechanism of Acquired Resistance of Entrectinib venipuncyure, Entrectinib - ROS1 Fusion Positive, Non Small Cell Lung Cancer | Recruiting | Fudan University | 38 | 2025-01-15 | 2025-09-30 | |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC Entrectinib - Non-Small Cell Lung Cancer, ROS1 Gene Rearrangement | Not yet recruiting | National Cancer Center, China | 40 | 2024-12-01 | 2024-11-19 | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Ipatasertib, Tiragolumab, Atezolizumab - Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 100 | 2023-06-01 | 2026-10-02 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Alectinib, Entrectinib, Durvalumab - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 68 | 2022-11-01 | 2026-11-02 |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Decitabine and Cedazuridine, Entrectinib, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 13 | 2022-10-28 | 2026-10-15 |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II Alectinib, Atezolizumab, Erlotinib - Solid Tumor, Advanced Solid Tumor | Active not recruiting | Seoul National University Bundang Hospital | 1000 | 2022-09-28 | 2026-09-30 | |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2024-07-15 |
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Entrectinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Hoffmann-La Roche | 217 | 2021-09-30 | 2026-08-13 |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma | Phase 2 | Recruiting | West China Hospital | 75 | 2021-06-01 | 2024-12-05 |
| Improving Public Cancer Care by Implementing Precision Medicine in Norway Atezolizumab - Cancer Metastatic | Phase 2 | Recruiting | Oslo University Hospital | 3000 | 2021-04-01 | 2024-02-29 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Entrectinib, Alectinib, Atezolizumab - Solid Tumors | Phase 2 | Active not recruiting | Hoffmann-La Roche | 920 | 2021-01-18 | 2026-09-04 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Entrectinib, Letrozole, Goserelin - Invasive Lobular Breast Carcinoma, ER+ Breast Cancer | Phase 2 | Unknown | Jules Bordet Institute | 65 | 2021-01-14 | 2024-12-04 |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy | Phase 2 | Completed | Genentech, Inc. | 252 | 2021-01-13 | 2025-01-08 |
| Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma PAC-1, Entrectinib - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Arkadiusz Z. Dudek, MD | 6 | 2021-01-11 | 2023-11-22 |
Showing 20 of 38. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (10) · Neoplasm Metastasis (5) · Brain Neoplasms (4) · Breast Neoplasms (4) · Hematologic Neoplasms (4) · Neoplasms (4) · Sarcoma (4) · Glioma (3) · Melanoma (3) · Pancreatic Neoplasms (3) · Central Nervous System Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2)
Hoffmann-La Roche (12) · Genentech, Inc. (3) · OHSU Knight Cancer Institute (3) · Cancer Research UK (2) · Fudan University (2) · Alliance for Clinical Trials in Oncology (1) · Arkadiusz Z. Dudek, MD (1) · Fondazione per la Medicina Personalizzata (1) · Helsinki University Central Hospital (1) · Hunan Province Tumor Hospital (1) · Jules Bordet Institute (1) · National Cancer Center, China (1) · Oslo University Hospital (1) · Peking University Shenzhen Hospital (1) · Pfizer (1)
United States (17) · China (11) · France (9) · United Kingdom (9) · Italy (8) · South Korea (8) · Germany (7) · Belgium (6) · Brazil (6) · Japan (6) · Poland (6) · Spain (6) · Australia (5) · Mexico (5) · Taiwan (5)
Matthew Krebs, Dr (2) · Adil Daud (1) · Andrea Botticelli (1) · Arkadiusz Dudek, MD, PhD (1) · Daniel Moreira, MD, MEd (1) · Dongmei Ji, M.D (1) · E.E. Voest, prof. (1) · Gary Deutsch, MD (1) · Katriina Jalkanen, MD, PhD (1) · Kenneth Gundle, MD (1) · Lara Davis (1) · Lara Davis, MD (1)
PMID 31838007, PMID 40086048, PMID 31838015, PMID 33646820, PMID 34427452, PMID 39549678, PMID 41213248, PMID 26565381, PMID 26884591, PMID 29118225, PMID 32299817, PMID 32479604, PMID 34924145, PMID 35086719, PMID 35119530, PMID 35395680, PMID 35568909, PMID 35598186, PMID 35695563, PMID 35995953, PMID 36870947, PMID 36924196, PMID 37424386, PMID 37738028, PMID 38190582, PMID 38630551, PMID 38724991, PMID 38848521, PMID 38898120, PMID 39096924, PMID 39863139, PMID 39934586, PMID 40304938, PMID 40341199, PMID 40525978, PMID 41023484, PMID 41392942, PMID 41963505, PMID 41986720, PMID 42691436
2023 (5), 2019 (3), 2017 (2), 2015 (1), 2018 (1), U10CA180821 (1)